Search Results
Aug 18, 2026, 10:33 ET Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsight
Novartis, Telix Pharmaceuticals, Xenon Pharmaceuticals, Pfizer, Exelixis, Ipsen Pharma, Takeda, Promontory Therapeutics, Xencor, Blue Earth Therapeutics, ORIC Pharmaceuticals, Curium, Fusion Pharmaceuticals, Merck, Orion, Kangpu Biopharmaceuticals, Lantheus, Eli Lilly and Company, Sanofi, Bayer, Johnson &
More news about: DelveInsight Business Research, LLP
Jul 13, 2026, 10:31 ET Metastatic Castration-resistant Prostate Cancer Market Poised for Strong Growth by 2036, Due to the Launch of Drug Classes Such as Anti-B7-H3 ADC, PROTAC Protein Degrader, NTD AR Inhibitor, Radionuclide Therapy, and Several Others | DelveInsight
Novartis, Telix Pharmaceuticals, Xenon Pharmaceuticals, Pfizer, Exelixis, Ipsen Pharma, Takeda, Promontory Therapeutics, Xencor, Blue Earth Therapeutics, ORIC Pharmaceuticals, Curium, Fusion Pharmaceuticals, Merck, Orion, Kangpu Biopharmaceuticals, Lantheus, Eli Lilly and Company, Sanofi, Bayer, Johnson &
More news about: DelveInsight Business Research, LLP
Jul 02, 2026, 10:31 ET Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsight
BlossomHill Therapeutics, Scorpion Therapeutics, Pierre Fabre, Antares Therapeutics, A2 Biotherapeutics, BioNTech, Dragonfly Therapeutics, Merus, DualityBio, ORIC Pharmaceuticals, BeOne Medicines (formerly BeiGene), Dizal Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Boehringer Ingelheim, Pfizer, Johnson &
More news about: DelveInsight Business Research, LLP
Jun 15, 2026, 12:31 ET EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight
(Dragonfly Therapeutics), Pamvatamig (MCLA-129) (Merus), TAS3351 (Taiho Oncology), DB-1310 (DualityBio), Enozertinib (ORIC-114) (ORIC Pharmaceuticals), BG-60366 (BeOne Medicines), and others. The expected launch of these therapies shall further create a positive impact
More news about: DelveInsight Business Research, LLP
May 21, 2026, 16:40 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 18, 2026, 10:01 ET Global Radiopharmaceuticals Market Set for Significant Expansion at a CAGR of ~10% by 2034 with Increasing Adoption of Targeted Radiotherapy | DelveInsight
Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, and others.
More news about: DelveInsight Business Research, LLP
May 14, 2026, 20:15 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 07, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Apr 30, 2026, 22:40 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Apr 16, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Mar 12, 2026, 10:01 ET Radioligand Therapies Market Set for Significant Growth by 2034, Driven by Rising Cancer Burden and Targeted Radiopharmaceutical Innovation | DelveInsight
Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, and others.
More news about: DelveInsight Business Research, LLP
Feb 10, 2026, 17:31 ET PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight
Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, among others.
More news about: DelveInsight Business Research LLP
Jan 20, 2026, 17:31 ET PSMA-Targeted Therapy Market Set to Expand by 2034 on Strong Pipeline and Increasing Diagnosis Rates | DelveInsight
Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, among others.
More news about: DelveInsight Business Research, LLP
Jan 14, 2026, 10:52 ET Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
ONCY), Nurix Therapeutics (NASDAQ: NRIX), Erasca (NASDAQ: ERAS), Foghorn Therapeutics (NASDAQ: FHTX), and ORIC Pharmaceuticals (NASDAQ: ORIC).
More news about: Equity Insider
Jan 12, 2026, 20:44 ET Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies
platforms are also yielding multiple next-generation CAR-T products with multi-targets and multi-mechanism designs. The innovative secreting CAR-T, OriC902, has shown groundbreaking efficacy and durability in ultra-late-line and difficult-to-treat solid tumor patients. Additionally, the company has initiated
More news about: OriCell Therapeutics Co., Ltd.
Jan 05, 2026, 17:31 ET Castration-sensitive Prostate Cancer Market Projected to Grow at a 13.2% CAGR (2020-2034), Driven by Expanded Approval and Wider Commercialization Opportunity in nmCSPC Segment | DelveInsight
Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, among others.
More news about: DelveInsight Business Research, LLP
Nov 05, 2025, 13:41 ET Drug Hunter, Inc. Announces the Appointment of Dr. Lori Friedman, Ph.D., to its Scientific Advisory Board
validation will be key as we continue to expand Drug Hunter's scope in drug discovery biology." Dr. Friedman is currently CSO of ORIC and has over 20 years of experience in cancer research, including expertise in cancer target discovery and validation, signal transduction, cancer genetics,
More news about: Drug Hunter
Oct 15, 2025, 17:31 ET Gastrointestinal Neuroendocrine Tumors Market Set to Surge by 2034 Amidst Advancements in Treatment Options | DelveInsight
& Dohme LLC, BioXcel Therapeutics Inc, Boehringer Ingelheim, RayzeBio, Inc., Vyriad, Inc., Hoffmann-La Roche, Monte Rosa Therapeutics, Inc, Amgen, ORIC Pharmaceuticals, among others.
More news about: DelveInsight Business Research, LLP